Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab—a report from the BELOB trial

Podobne zapisy

• OS4.2 Radiological response assessment in the era of bevacizumab: RANO or volumetry? A report from the BELOB trial.
  od: Gahrmann, R., i wsp.
  Wydane: (2016)
• ATCT-31 CENTRAL RADIOLOGY REVIEW OF THE BELOB TRIAL: TREATMENT WITH BEVACIZUMAB IN RECURRENT GLIOBLASTOMA IS ASSOCIATED WITH MORE FREQUENT NON-ENHANCING PROGRESSION
  od: Smits, Marion, i wsp.
  Wydane: (2015)
• AT-55 FINAL ANALYSIS OF THE BELOB TRIAL (A RANDOMIZED PHASE II STUDY ON BEVACIZUMAB VERSUS BEVACIZUMAB PLUS LOMUSTINE VERSUS LOMUSTINE SINGLE AGENT IN RECURRENT GLIOBLASTOMA) AND FIRST RADIOLOGY REVIEW RESULTS
  od: Taal, Walter, i wsp.
  Wydane: (2014)
• GE-10 IDENTIFICATION OF PATIENTS WITH RECURRENT GBM THAT BENEFIT FROM BEVACIZUMAB
  od: Eraslan, Lale Erdem, i wsp.
  Wydane: (2014)
• Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial
  od: Beije, N, i wsp.
  Wydane: (2015)